Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery

NCT06300411 is registered in ClinicalTrials.gov with SURGE Therapeutics as lead sponsor.

NCT NCT06300411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06300411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery
Lead sponsor
SURGE Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 29, 2024
Completion date
April 8, 2026
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer